S893
Clinical - Mixed sites & palliation
ESTRO 2026
References: Zhao, Y., Zhang, Y., Ye, J., Liu, X., Yang, H., Cong, F. ... Ye, H. (2016). Hepatic resection versus transarterial chemoembolization for patients with Barcelona Clinic
during follow-up, predominantly intrahepatic out-of- field or extrahepatic. Within the studied dose fractionations (45 Gy/3fx; 50–60 Gy/6fx), no dose– response signal was evident for time-to-progression or survival on descriptive analyses.In a contextual comparison with historical TACE cohorts, when compared to the data from \cite, statistical difference seems to exist for 6, 9 and 12 month survival (p-value 0.036, 0.032 and 0.008, respectively. Bilateral). Also, when survival curves are compared for both treatments, statistical differences are also found with great significance (p-value=0.0000016; log-rank). However, this cross-study comparison is exploratory and hypothesis-generating only, given differences in selection and methodology.
Liver Cancer intermediate stage Child-Pugh A hepatocellular carcinoma. Experimental and Therapeutic Medicine, 12, 3813-3819. Keywords: Hepatocellular carcinoma, SBRT
Digital Poster 3312 Hemostatic radiotherapy: what contribution does it make to the treatment of gastric tumors? Sanae Lamarti 1 , Khadija Saadi 1 , Houda Ibroun 1 , Ibtissam Touffahi 1 , Adil Gourinda 2 , Wafaa Marsetti 1 , Soukaina Morchid 1 , Nabila Sellal 1 1 radiotherapy, Mohammed VI University Hospital, tangier, Morocco. 2 epidemiology, Mohammed VI University Hospital, tangier, Morocco Purpose/Objective: Gastrointestinal bleeding is a serious and potentially life-threatening complication of gastric cancer, particularly in locally advanced stages. Among the available therapeutic options, radiotherapy (RT) represents a non-invasive alternative, especially in cases where other treatments have failed or are contraindicated [1].The objective of this study is to evaluate the effectiveness of radiotherapy in controlling gastric tumor bleeding. Material/Methods: We conducted a retrospective study between April 2017 and October 2024 including all patients who received hemostatic radiotherapy for gastric tumors at the Radiotherapy Department of Mohammed VI University Hospital in Tangier. Successful hemostasis was defined as at least one month of survival without rebleeding or additional transfusion. Results: A total of 19 patients were included. The median age was 56.2 years, with a sex ratio of 1.5 (64% male). Overall, 68% presented with grade 1 bleeding, and the remainder with grade 2 bleeding. Fourteen patients required blood transfusion, one underwent arterial embolization, and two received endoscopic treatment. Regarding the radiotherapy regimen, a dose of 20Gy in 5 fractions (BED 28 Gy) was used in 12 patients, 3 patients received 30Gy in 10 fractious (BED 39Gy), and 4 patients received a single fraction of 8 Gy(BED 14.4 Gy). Radiotherapy was administered using 3D technology in all patients and was generally well tolerated, Only two patients developed grade 1 radiation-induced gastritis.Hemostasis was achieved in 78% of cases. The BED 28 Gy regimen demonstrated
Conclusion: SBRT for unresectable/recurrent HCC yielded
favorable survival with excellent tolerability and no ≥ G2 toxicity in this real-world cohort. Roughly half of patients progressed over follow-up, but no clear dose– response was seen among commonly used regimens (45 Gy/3fx; 50–60 Gy/6fx). When considered alongside historical data, there seems to be significant difference between SBRT and TACE, according to the results shown by Zhao et. al., showing that SBRT might be a valuable tool in HCC treatment, with a much higher survival.
Made with FlippingBook - Share PDF online